Full Text Journal Articles by
Author Jimmy J Hwang

Advertisement

Find full text journal articles






Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review.

Mike Fruscione, Ryan C Pickens, Erin H Baker, John B Martinie, David A Iannitti, Jimmy J Hwang, Dionisios Vrochides,

Intrahepatic cholangiocarcinoma (ICC) is a devastating malignant neoplasm with dismal outcomes. Several therapeutic modalities have been used with variable success to downsize these tumors for resection. Neoadjuvant therapy such as chemoembolization and radioembolization offer promising options to manage tumor burden prior to resection. A systematic review of the literature was ... Read more >>

Curr Probl Cancer (Current problems in cancer)
[2020, :100614]

Cited: 0 times

View full text PDF listing >>



Advances in borderline resectable pancreatic adenocarcinoma.

Deepak Vadehra, Patrick N Salibi, Derek R McHaffie, Jesse Sulzer, David A Iannitti, Jimmy J Hwang,

Pancreatic adenocarcinoma is one of the most lethal cancers in oncology. Pancreatic cancer is the third most common cause of cancer-related mortality in the United States. As the years have progressed, the importance of a multidisciplinary and multimodal approach to pancreatic cancer care has been recognized and is now recommended ... Read more >>

Clin Adv Hematol Oncol (Clinical advances in hematology & oncology : H&O)
[2020, 18(5):280-288]

Cited: 0 times

View full text PDF listing >>



Advertisement

Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma.

Matthew K Stein, Forrest W Williard, Joanne Xiu, Miriam W Tsao, Michael G Martin, Benjamin W Deschner, Paxton V Dickson, Evan S Glazer, Danny Yakoub, David Shibata, Axel F Grothey, Philip A Philip, Jimmy J Hwang, Anthony F Shields, John L Marshall, W Michael Korn, Heinz-Josef Lenz, Jeremiah L Deneve,

BACKGROUND AND OBJECTIVES:Peritoneal metastases (PM) from primary colorectal cancer (pCRC) are associated with poor outcomes; however, molecular differences are not well defined. METHODS:We compared unpaired tumor profiles of patients with pCRC and PM from Caris Life Sciences. Testing included next-generation sequencing of 592 genes, microsatellite instability (MSI) and tumor mutational ... Read more >>

J Surg Oncol (Journal of surgical oncology)
[2020, 121(8):1320-1328]

Cited: 0 times

View full text PDF listing >>



Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.

Benjamin A Weinberg, Joanne Xiu, Michael R Lindberg, Anthony F Shields, Jimmy J Hwang, Kelsey Poorman, Mohamed E Salem, Michael J Pishvaian, Randall F Holcombe, John L Marshall, Michael A Morse,

Background:Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare malignancies with limited standard chemotherapeutic options for advanced disease. Recent studies have demonstrated potential novel biliary cancer targets and a possible role for immunotherapy in the treatment of patients with this disease. Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and ... Read more >>

J Gastrointest Oncol (Journal of gastrointestinal oncology)
[2019, 10(4):652-662]

Cited: 0 times

View full text PDF listing >>



Frequency of unplanned surgery in patients with stage IV colorectal cancer receiving palliative chemotherapy with an intact primary: An analysis of SEER-Medicare.

Patrick D Lorimer, Benjamin M Motz, Russell C Kirks, Yimei Han, James T Symanowski, Jimmy J Hwang, Jonathan C Salo, Joshua S Hill,

BACKGROUND AND OBJECTIVES:Stage IV colorectal cancer is often treated with palliative chemotherapy with the primary tumor in place. Low rates of unplanned surgical intervention (due to obstruction or perforation) have been reported. We examined a large national dataset to determine the rate of unplanned surgical intervention in these patients. METHODS:Surveillance ... Read more >>

J Surg Oncol (Journal of surgical oncology)
[2019, 120(3):407-414]

Cited: 0 times

View full text PDF listing >>



Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.

Ryuma Tokunaga, Joanne Xiu, Curtis Johnston, Richard M Goldberg, Philip A Philip, Andreas Seeber, Madiha Naseem, Jae Ho Lo, Hiroyuki Arai, Francesca Battaglin, Alberto Puccini, Martin D Berger, Shivani Soni, Wu Zhang, Jimmy J Hwang, Anthony F Shields, John L Marshall, Hideo Baba, W Michael Korn, Heinz-Josef Lenz,

PURPOSE:The natural history and prognosis of appendiceal adenocarcinomas differ from those of adenocarcinomas arising in other large bowel sites. We aimed to compare the molecular profiles exhibited by appendiceal adenocarcinomas and colorectal cancers, or between the histopathologic subtypes of appendiceal adenocarcinoma. EXPERIMENTAL DESIGN:A total of 183 samples from appendiceal adenocarcinoma ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, 25(10):3096-3103]

Cited: 0 times

View full text PDF listing >>



A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Michael J Pishvaian, Rebecca S Slack, Wei Jiang, A Ruth He, Jimmy J Hwang, Amy Hankin, Karen Dorsch-Vogel, Divyesh Kukadiya, Louis M Weiner, John L Marshall, Jonathan R Brody,

BACKGROUND:Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging agents such as temozolomide. The sensitizing effects of PARP inhibitors are magnified when cells harbor DNA repair defects. METHODS:A single-arm, open-label, phase 2 study was performed to investigate the disease ... Read more >>

Cancer (Cancer)
[2018, 124(11):2337-2346]

Cited: 5 times

View full text PDF listing >>



Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.

Benjamin A Weinberg, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, Mohamed E Salem, John L Marshall,

PURPOSE:The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD-L1) protein by companion diagnostic testing. However, some patients with PD-L1-negative ... Read more >>

Oncologist (The oncologist)
[2018, 23(10):1171-1177]

Cited: 2 times

View full text PDF listing >>



Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.

Mohamed E Salem, Alberto Puccini, Axel Grothey, Derek Raghavan, Richard M Goldberg, Joanne Xiu, W Michael Korn, Benjamin A Weinberg, Jimmy J Hwang, Anthony F Shields, John L Marshall, Philip A Philip, Heinz-Josef Lenz,

The efficacy of immunotherapy varies widely among different gastrointestinal cancers. Response to immune checkpoint inhibitors is shown to correlate with tumor mutation load (TML), mismatch repair deficiency (dMMR) status, and programmed cell death-ligand 1 (PD-L1) expression. Herein, we quantify TML, dMMR, and PD-L1 expression and determine their interrelationship in gastrointestinal ... Read more >>

Mol. Cancer Res. (Molecular cancer research : MCR)
[2018, 16(5):805-812]

Cited: 11 times

View full text PDF listing >>



A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.

John F Deeken, Hongkun Wang, Marion Hartley, Amrita K Cheema, Brandon Smaglo, Jimmy J Hwang, Aiwu Ruth He, Louis M Weiner, John L Marshall, Giuseppe Giaccone, Stephen Liu, Jim Luecht, Jay Y Spiegel, Michael J Pishvaian,

PURPOSE:The artemisinin class of anti-malarial drugs has shown significant anti-cancer activity in pre-clinical models. Proposed anti-cancer mechanisms include DNA damage, inhibition of angiogenesis, TRAIL-mediated apoptosis, and inhibition of signaling pathways. We performed a phase I study to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of intravenous artesunate ... Read more >>

Cancer Chemother. Pharmacol. (Cancer chemotherapy and pharmacology)
[2018, 81(3):587-596]

Cited: 7 times

View full text PDF listing >>



Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.

Mohamed E Salem, Benjamin A Weinberg, Joanne Xiu, Wafik S El-Deiry, Jimmy J Hwang, Zoran Gatalica, Philip A Philip, Anthony F Shields, Heinz-Josef Lenz, John L Marshall,

Tumor sidedness has emerged as an important prognostic and predictive factor in the treatment of colorectal cancer. Recent studies demonstrate that patients with advanced right-sided colon cancers have a worse prognosis than those with left-sided colon or rectal cancers, and these patient subgroups respond differently to biological therapies. Historically, management ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(49):86356-86368]

Cited: 24 times

View full text PDF listing >>



Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer.

Marwan Al-Hajeili, Anthony F Shields, Jimmy J Hwang, Raymond C Wadlow, John L Marshall,

Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient. Proper utilization of these biomarkers can enable physicians to tailor therapeutic strategies to maximize the likelihood of ... Read more >>

Oncology (Williston Park, N.Y.) (Oncology (Williston Park, N.Y.))
[2017, 31(4):301-312]

Cited: 1 time

View full text PDF listing >>



Optimizing the management of hepatobiliary neoplasms: a multidisciplinary and molecular challenge.

Kunal C Kadakia, Jimmy J Hwang,

J Gastrointest Oncol (Journal of gastrointestinal oncology)
[2017, 8(2):213-214]

Cited: 0 times

View full text PDF listing >>



The challenge of measuring intra-individual change in fatigue during cancer treatment.

Carol M Moinpour, Gary W Donaldson, Kimberly M Davis, Arnold L Potosky, Roxanne E Jensen, Julie R Gralow, Anthony L Back, Jimmy J Hwang, Jihye Yoon, Debra L Bernard, Deena R Loeffler, Nan E Rothrock, Ron D Hays, Bryce B Reeve, Ashley Wilder Smith, Elizabeth A Hahn, David Cella,

To evaluate how well three different patient-reported outcomes (PROs) measure individual change.Two hundred and fourteen patients (from two sites) initiating first or new chemotherapy for any stage of breast or gastrointestinal cancer participated. The 13-item FACIT Fatigue scale, a 7-item PROMIS® Fatigue Short Form (PROMIS 7a), and the PROMIS® Fatigue ... Read more >>

Qual Life Res (Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation)
[2017, 26(2):259-271]

Cited: 0 times

View full text PDF listing >>



Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.

Xuefei Tian, Narayan Shivapurkar, Zheng Wu, Jimmy J Hwang, Michael J Pishvaian, Louis M Weiner, Lisa Ley, Dan Zhou, Xiuling Zhi, Anton Wellstein, John L Marshall, Aiwu Ruth He,

Patients exhibiting pancreatic cancer possess poor rates of survival. Therefore, the identification of a biomarker that can be measured non-invasively and be used to predict patient outcomes is required for the successful treatment of pancreatic cancer. The present study evaluated serum microRNA (miRNA/miR) profiles in patients exhibiting pancreatic cancer, who ... Read more >>

Oncol Lett (Oncology letters)
[2016, 11(3):1645-1650]

Cited: 6 times

View full text PDF listing >>



Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.

Zheng Wu, Andrew Gabrielson, Jimmy J Hwang, Michael J Pishvaian, Louis M Weiner, Tingting Zhuang, Lisa Ley, John L Marshall, Aiwu Ruth He,

Patients with metastatic, gemcitabine-refractory pancreatic cancer typically have poor survival. Erlotinib, a targeted therapy that inhibits epidermal growth factor receptor (EGFR) activity (overexpressed in 40-60 % of pancreatic cancers), was FDA approved for the treatment of patients with advanced pancreatic cancer. Human epidermal growth factor receptor 2 (HER-2), another member ... Read more >>

Cancer Chemother. Pharmacol. (Cancer chemotherapy and pharmacology)
[2015, 76(6):1309-1314]

Cited: 13 times

View full text PDF listing >>



Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study.

Benjamin A Weinberg, Hongkun Wang, Xuezhong Yang, Christina S Wu, Michael J Pishvaian, Aiwu R He, John L Marshall, Jimmy J Hwang,

The 5-year survival of pancreatic adenocarcinoma with surgery and adjuvant chemotherapy is below 25%. The original Gastrointestinal Tumor Study Group (GITSG) adjuvant study demonstrated a survival benefit attributed to weekly intravenous boluses of 5-fluorouracil (5-FU) for 2 years in addition to chemoradiation compared to surgery alone. In theory, the prolonged ... Read more >>

Gastrointest Cancer Res (Gastrointestinal cancer research : GCR)
[2014, 7(3-4):91-97]

Cited: 2 times

View full text PDF listing >>



A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Michael J Pishvaian, John L Marshall, Andrew J Wagner, Jimmy J Hwang, Shakun Malik, Ion Cotarla, John F Deeken, A Ruth He, Hirut Daniel, Abdel-Baset Halim, Hamim Zahir, Catherine Copigneaux, Kejian Liu, Robert A Beckman, George D Demetri,

Efatutazone (CS-7017), a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models. The authors conducted a phase 1 study to determine the recommended phase 2 dose, safety, tolerability, and pharmacokinetics of efatutazone.Patients with advanced solid malignancies and no curative therapeutic options were enrolled to receive a ... Read more >>

Cancer (Cancer)
[2012, 118(21):5403-5413]

Cited: 30 times

View full text PDF listing >>



Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.

Pamela L Kunz, Aiwu R He, A Dimitrios Colevas, Michael J Pishvaian, Jimmy J Hwang, Pamela L Clemens, Marianne Messina, Remigiusz Kaleta, Fernanda Abrahao, Branimir I Sikic, John L Marshall,

Ixabepilone, which stabilizes microtubules, has low susceptibility to drug resistance mediated by P-glycoprotein or βIII-tubulin.This study was designed to determine the maximum tolerated dose (MTD) of oral ixabepilone when administered every 6 h for three doses, every 3 weeks, to patients with refractory advanced cancers. Eighteen patients were treated with ... Read more >>

Invest New Drugs (Investigational new drugs)
[2012, 30(6):2364-2370]

Cited: 5 times

View full text PDF listing >>



Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.

Jimmy J Hwang, John Kuruvilla, David Mendelson, Michael J Pishvaian, J F Deeken, Lillian L Siu, Mark S Berger, Jean Viallet, John L Marshall,

Two phase I, single-agent studies were conducted to determine the dose and regimen of obatoclax, an antagonist of all BCL-2 antiapoptotic proteins, for evaluation in phase II trials. The two studies, GX001 and GX005, evaluated the safety and tolerability of weekly 1-hour and 3-hour infusions of obatoclax, respectively.Eligible patients in ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2010, 16(15):4038-4045]

Cited: 58 times

View full text PDF listing >>



Role of chemotherapy in the treatment of gastroesophageal cancers.

Jimmy J Hwang,

Esophageal, gastroesophageal junction, and gastric cancers are underpublicized but are frequently lethal, and gastroesophageal junction adenocarcinomas are increasingly common diseases in the United States and around the world. Although often grouped together in studies of chemotherapy, clear distinctions can be made in the locoregional therapy of these diseases. Esophageal squamous ... Read more >>

Oncology (Williston Park, N.Y.) (Oncology (Williston Park, N.Y.))
[2007, 21(5):579-86; discussion 587, 591-2]

Cited: 5 times

View full text PDF listing >>



Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.

Jimmy J Hwang,

Variations of fluorouracil (5-FU) therapy have formed the backbone of chemotherapy for advanced colorectal cancer for many years. With the advent of newer agents that often work best with or even require chemotherapy to optimize their activity, the issue of the optimal schedule and regimen of administration of 5-FU has ... Read more >>

Oncology (Williston Park, N.Y.) (Oncology (Williston Park, N.Y.))
[2004, 18(14 Suppl 14):26-34]

Cited: 3 times

View full text PDF listing >>



Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.

Ramesh K Ramanathan, Jimmy J Hwang, William C Zamboni, Frank A Sinicrope, Howard Safran, Michael K Wong, Martin Earle, Adam Brufsky, Terry Evans, Monica Troetschel, Christine Walko, Roger Day, Helen X Chen, Sydney Finkelstein,

BACKGROUND:To determine the response rate of trastuzumab and irinotecan in HER-2/neu overexpressing advanced colorectal cancer (CRC), determine the frequency of HER-2/neu expression in CRC, and evaluate the pharmacokinetics of trastuzumab in a phase II study. PATIENTS AND METHODS:Patients were screened for HER-2/neu by immunohistochemistry (DAKO HercepTest). Prior chemotherapy was limited ... Read more >>

Cancer Invest. (Cancer investigation)
[2004, 22(6):858-865]

Cited: 59 times

View full text PDF listing >>



Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.

Jimmy J Hwang, Steven G Eisenberg, John L Marshall,

Irinotecan (CPT-11, Camptosar) is one of the new generation of chemotherapeutic agents that has activity in advanced colorectal cancer. It has antitumor efficacy as a single agent, and also has been combined with fluorouracil (5-FU) and leucovorin (IFL) to treat these patients. Randomized studies have confirmed the superiority of IFL ... Read more >>

Oncology (Williston Park, N.Y.) (Oncology (Williston Park, N.Y.))
[2003, 17(9 Suppl 8):37-43]

Cited: 2 times

View full text PDF listing >>



Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.

Jimmy J Hwang, John L Marshall, Naiyer Rizvi,

Preclinical data suggest that the combination of inhibitors of topoisomerases I and II may be synergistic when administered together. The optimal sequence of such combinations is uncertain, but initial administration of a topoisomerase I inhibitor upregulates topoisomerase II. Several combinations of these inhibitors have been evaluated, but have not clearly ... Read more >>

Oncology (Williston Park, N.Y.) (Oncology (Williston Park, N.Y.))
[2003, 17(5 Suppl 5):46-51]

Cited: 5 times

View full text PDF listing >>



Advertisement

Disclaimer
1.7233 s